



IBIO-101

IL-2 Sparing Anti-CD25

IBIO-101 for Regulatory T-Cell (T_{reg}) Depletion

Target Mechanism

Depletion of immunosuppressive T_{regs} via antibody dependent cellular cytotoxicity (ADCC), without disrupting activation of effector T-cells (T_{effs}) in the tumor microenvironment


Potential Indications

- Solid tumors
- Hairy cell leukemia
- Relapsed mult. myeloma
- Lymphoma
- Head & neck cancer

Differentiation / Opportunity

- IL-2 sparing anti-CD25 antibodies enables depletion of T_{regs} without affecting T_{effs}
- Fast-follower to Roche's RG6292 clinical molecule


Recent Transactions & Milestones



*Roche acquisition of Tusk Therapeutics completed for €70M upfront, acquiring worldwide rights to anti-CD25 program. Values converted to dollars as reported in public press releases

**Data presented by Roche at AACR 2023

IBIO-101 Reduces Tumor Growth in Preclinical Studies by Selectively Depleting Immunosuppressive T_{reg} s without Affecting Cancer Killing T_{eff} s




1st gen CD25 mAbs depleted immuno-suppressive T_{reg} and immuno-stimulatory T_{eff}

Limited efficacy

2nd gen IBIO-101 selectively targets T_{reg} s without blocking IL-2 signaling to T_{eff} s

Strong preclinical anti-tumor response

IBIO-101 Selectively Depletes Tregs




IBIO-101 potently binds recombinant CD25


while preserving IL-2 signaling

which leads to T_{reg} depletion


while sparing T_{eff} s




- Negative control, EC_{50} = no binding
- IBIO-101, EC_{50} = 16.4 ng/ml
- RG6292 (Roche), EC_{50} = 24.7 ng/ml



- IL2, EC_{50} = 0.11 ng/ml
- IBIO-101, EC_{50} = 0.17 ng/ml
- RG6292, EC_{50} = 0.14 ng/ml



- Negative control, EC_{50} = no cell killing
- IBIO-101, EC_{50} = 4.7 ng/ml
- RG6292, EC_{50} = 18.6 ng/ml





- T_{reg} killing, EC_{50} = 7.09 ng/ml
- Activated $CD4^+$ T_{eff} killing, EC_{50} = no activity
- Activated $CD8^+$ T_{eff} killing, EC_{50} = no activity




IBIO-101 Increases in $T_{\text{eff}}/T_{\text{reg}}$ Ratio in Preclinical Studies Inhibiting Tumor Growth

Potently increases T-eff/T-reg ratio¹



Tumor growth inhibition correlates with T-eff/T-reg ratio



IBIO-101 in Combination With a Checkpoint Inhibitor Shows Greater Efficacy

IBIO-101 + PD-1 Checkpoint Inhibitor In PreClinical Studies Enhances Tumor Suppression

